World-leading innovative stem cell therapy

Stem cell therapy at the Isar Clinic in Munich is a cutting-edge treatment that is paving the way for the future of medicine. This treatment is a safe and effective method approved by the FDA, giving hope to many patients. One of the most notable is Professor Orth's unique stem cell therapy, which uses innovative techniques that go beyond conventional cultured stem cell therapy and provides more effective and safer results.

Prof. Eckhard Alt

Professor Orth is a world authority on regenerative medicine and stem cell therapy.

For many years, we have been engaged in the research and clinical application of stem cell therapy, and our innovative approach has brought about improvements for many patients. In particular, we boast a high success rate in therapies using the patient's own cells, providing safer and more effective results than other treatments.

He currently practices cutting-edge stem cell therapy at the Issar Clinic in Munich, Germany, where he treats a wide range of illnesses, including joint disorders, neurological problems, and heart disease. His treatments are FDA approved, and many patients from around the world come to Professor Orth for treatment.

What is Professor Ortho's stem cell therapy?

Professor Orth is a world-renowned authority in the field of stem cell therapy. The treatment he developed based on his research and clinical experience is different from the typical treatments that involve harvesting and culturing stem cells. Instead of culturing stem cells, he uses his own technology to rapidly use the patient's own cells to maximize the patient's self-repair ability.

Fast acting and highly effective

Traditional stem cell therapies can take weeks or even months to harvest and then cultivate the cells, but Professor Orth's treatment allows the stem cells to be directly injected back into the patient's body, speeding up the healing process.

Safe and Natural Treatment

Growing cells outside the body carries with it risks from contamination and inappropriate culture conditions. However, Professor Orth's treatment uses stem cells directly from the patient's body, which significantly reduces these risks. Furthermore, by using the patient's own cells, there is no risk of rejection.

Wide range of treatment options

This treatment is applicable to a wide range of diseases, including joint diseases, nervous system problems, heart disease, skin regeneration, etc. Compared to cultured stem cell therapy, Professor Ortho's treatment is more effective for a wide range of diseases and has a shorter recovery time.

The era of stem cell therapy without culture

From now on, the use of cultured ADSC (Adipose-Derived Stem Cells) and MSC (Mesenchymal Stem Cells) will be replaced by the use of fresh, uncultured UA-ADRC (Uncultured Adipose-Derived Regenerative Cells) in autologous adipose-derived stem cell therapy.

Cellular characteristics and diversity

UA-ADRCs contain a variety of cellular components because they are used without being cultured after being extracted from adipose tissue. These include progenitor cells, vascular endothelial cells, smooth muscle cells, immune cells, stem cells, etc., and are highly diverse. It is believed that the cooperation of these diverse cell groups enhances tissue repair and regeneration capabilities.
On the other hand, cultured ADSCs and MSCs focus on specific cell populations (mainly stem cells), so the diversity of UA-ADRCs is likely to be lost, and there is a risk that the characteristics of stem cells may change over long-term culture.

Changes in immune characteristics

Cultured ADSCs and MSCs are at risk of increased immunogenicity during the culture process because the antigenic structure of the cell surface changes when the cells are cultured outside the body for a long period of time, increasing the possibility of causing rejection by the immune system.
On the other hand, because UA-ADRCs are used immediately without being cultured, they retain the immune characteristics they had immediately after collection, which makes them more likely to exert natural immunosuppressive effects and reduce rejection reactions after transplantation.

Cell aging and decline in activity

There is a risk of senescence in stem cell culture. As the cells undergo proliferation cycles in the culture process, their ability to divide decreases and their activity required for repair and regeneration may also decrease. This is especially problematic when cultured for long periods or when passages are repeated.
Because UA-ADRCs are fresh and used immediately after collection, the cells are likely still young and highly active, and therefore are expected to have a high repair capacity suitable for regenerative medicine purposes.

Adaptability of cells to their natural environment

Because cultured ADSCs and MSCs are grown in an artificial environment, their ability to adapt to the natural environment in the body after transplantation may be weakened, which may limit their ability to exert their functions in the body.
Because UA-ADRCs are not cultured, they are likely to quickly adapt to the natural environment inside the body and are therefore expected to have a high survival rate and function after transplantation.

InGneron, a global leader in stem cell therapy

Founded by Professor Orth, InGneron is at the forefront of regenerative medicine and is a leader in stem cell therapy innovation, bringing new hope to a variety of diseases that have not been treated with conventional treatments by maximizing the body's inherent regenerative powers.

US Office

InGeneron, Inc.
8205 El Rio St Houston, TX
77054 USA

https://ingeneron.com/

InGeneron

Scientific evidence-based stem cell therapy

InGneron provides treatments that are backed by scientific evidence. InGneron's technology has been proven highly effective and safe through animal and clinical testing, and is widely used in medical institutions around the world. In particular, treatments using stem cells derived from autologous adipose tissue have shown excellent results in the relief of chronic pain and improvement of joint diseases.

Cutting-edge treatment approved in Europe and the United States

InGneron's technology has been approved by regulatory authorities in the United States and Europe and is being rolled out globally. This approval makes InGneron's stem cell therapy a global standard, and more and more patients are benefiting from InGneron's innovative treatment. The approval in Europe and the United States was obtained after rigorous screening and is a testament to the reliability and effectiveness of InGneron's technology.

Creating the future of regenerative medicine

InGneron is relentlessly investing in research and development to pave the way for the future of stem cell therapy. Our goal is to provide new treatment options for diseases that have been difficult to treat and improve the quality of life for patients. As a pioneer in the field, InGneron is co-creating the future of regenerative medicine.

Bringing world-leading stem cell therapy to Japan

With the cooperation of Professor Orth, we are working to make this treatment available in Japan.

We provide support for travel to Munich where treatment can be received, as well as support for introducing this treatment to medical institutions in Japan.